Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131331) titled 'A Randomized Controlled Trial of Tofacitinib in Combination with Deucravacitinib versus Deucravacitinib Monotherapy for Moderate-to-Severe Plaque Psoriasis' on Sept. 1.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venerology, Shandong First Medical University & Shandong Academy of Medical Sciences
Condition:
Moderate to severe plaque psoriasis
Intervention:
Control group:Received deucravacitinib monotherapy at a dose of 6 mg once daily (qd).
Recruitment Status: Recruiting
Phase:...